TrialThe lancet. Diabetes & endocrinology2026

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.

Benjamin Z Leder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.